JJP Biologics: nebaprubart shows early efficacy in rare LAD trial
JJP Biologics has released positive interim data from its ongoing Phase 1b trial of nebaprubart (JJP-1212), an investigational anti-CD89 antagonist, in patients with Linear IgA Disease (LAD), a rare autoantibody-driven blistering skin condition. The Warsaw-based company said the data show a favourable safety and tolerability profile alongside early signs of clinical benefit, including reductions in blister formation and pruritus within one week of the first dose.
The interim results also showed progressive healing of ulcerative lesions and the sustained tapering of dapsone-based immunosuppressive therapy following treatment — a meaningful outcome in an indication where no therapies are currently approved in the European Union. JJP Biologics says the consistency between the safety profile observed in healthy volunteers during Phase 1 and the signals seen in LAD patients reduces clinical development risk for the programme.
Mechanism and proof of concept
Nebaprubart works by blocking the CD89 receptor on neutrophils, interrupting the pathway by which deposited IgA autoantibodies trigger tissue damage and widespread blistering. JJP Biologics has framed LAD as a deliberate proof-of-mechanism showcase: the disease's clearly visible, rapidly evolving skin manifestations make it possible to assess the drug's effect on the IgA/CD89 axis within days rather than months, providing a faster readout than more systemic IgA-mediated diseases might allow.
Chief medical officer Sohail Ahmed said the Phase 1b trial showed "predictable pharmacology and no dose-limiting toxicities," adding that the ability to taper or eliminate concomitant therapies that some patients struggle to tolerate was "highly meaningful for this patient population." Chief executive Paweł Szczepański described nebaprubart as "a potentially transformative therapy across a broad range of IgA-mediated diseases," though the company has not yet published peer-reviewed data or disclosed patient numbers from the interim cohort.
Pipeline expansion and competitive landscape
The company plans to initiate a Phase 1b trial of nebaprubart in rheumatoid arthritis in Q3 2026, followed by a Phase 2a basket study in IgA nephropathy in Q4 2026. The nephropathy indication is notable: it is a significantly larger commercial opportunity than LAD, and one that has attracted growing industry attention following the approval of sparsentan and the accelerated approval of budesonide in the United States for IgA nephropathy. Whether nebaprubart's CD89-blocking mechanism offers a differentiated profile versus complement inhibitors, endothelin antagonists, and SGLT2 inhibitors already in use or in late-stage development will be a key question for investors and clinicians as the company advances.
JJP Biologics says it is the first company to generate clinical validation of the IgA/CD89 axis, positioning itself as a first-mover in a mechanistic space with potential read-across to conditions including systemic lupus erythematosus, IgA vasculitis, coeliac disease, and idiopathic pulmonary fibrosis. The company is backed by the Starak family and Polpharma Group, and nebaprubart holds Orphan Medicinal Product designation from the European Commission for LAD. Full data from the Phase 1b LAD study are expected to be presented at a forthcoming medical meeting, and the near-term milestones — the RA trial start and nephropathy basket study initiation — will be closely watched as early tests of how broadly the platform can be applied.